Brief: Vaccinex Reports Clinical Benefit In Interim Analyses
31/10/2023 13:08
Oct 31 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS CLINICAL BENEFIT IN INTERIM ANALYSES FROM
TWO
PHASE 2 STUDIES OF PEPINEMAB COMBINATION TREATMENT AT SOCIETY
FOR IMMUNOTHERAPY OF CANCER’S ANNUAL MEETING
Source text for Eikon: ID:nGNX15Z0xB
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease